Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus neoadjuvant chemoradiotherapy in locally advanced rectal cancer
ChiCTR2600126919Phase 4Recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of serplulimab in rectal cancer, sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoint: clinical complete response rate (cCR). Started Jun 2026; status: recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2600126919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126919.